Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

Autor: C Cheneau, S Barthier, J Lemonnier, Fabrice Andre, C Dubot, L Teixeira, A Escande, T De La Motte Rouge, T Petit, L Arnould, Laurent Arnould, Suzette Delaloge, Jerome Lemonnier, A Marti, L Stefani, F Berger, C Levy, P Barthelemy, S Nguyen, M Gardner, A Lortholary, François-Clément Bidard, J Plaza, L Joly, Thibault de la Motte Rouge, F Andre, I Bièche, C Alleaume, R Sabatier, B Lucas, Ivan Bieche, O Derbel, L Venat-Bouvet, F Del Piano, Florian Clatot, Anne-Claire Hardy-Bessard, Frédérique Berger, Margaux Marce, Thomas Bachelot, Anne Pradines, Jean-Luc Canon, Sandrine Marques, M Achille, H Ammarguellat, O Arsene, T Bachelot, C Bernard-Marty, F-C Bidard, N Bonichon-Lamichhane, N Bonnin, R Bouaita, A Boudrant, V-A Brunel, C Chakiba, F Clatot, F Dalenc, A De Gramont, L Deiana, C Delbaldo, V Delecroix, H Desclos, V D'Hondt, N Dohollou, J-M Ferrero, C Foa, J-S Frenel, C Garnier Tixidre, D Genet, O Gisserot, M Gozy, C Greilsamer, J Grenier, F Guinet, A-C Hardy-Bessard, J-P Jacquin, E Lachaier, S Ladoire, A-P Laurenty, R Le Scodan, N Leduc, E Legouffe, C Levache, F Lorchel, N Marques, J Medioni, A Melis, D Mille, D Mollon, L Moreau, I Moullet, M-A Mouret-Reynier, A Najem, H Orfeuvre, J-F Paitel, B Pistilli, C Riedl, P Soulie, D Spaeth, F Trouboul, C Valmar, H Vegas, A Zannetti, FC Bidard, S Delaloge, A Pradines, JL Canon, S Marques

Publikováno v: BMJ Open, Vol 12, Iss 3 (2022)

Introduction The combination of a CDK4/6 inhibitor with an aromatase inhibitor (AI) has recently become the gold standard for AI-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2−) advanced breast cancer. Howev

Externí odkaz: https://doaj.org/article/8faf6bbc845f4ceeb90674dd08e198da

Abstract PD2-06: Circulating ESR1 mutation detection rate and early decrease under first line aromatase inhibitor and palbociclib in the PADA-1 trial (UCBG-GINECO)

Autor: Patrick Soulié, M-A Mouret-Reynier, A-C Hardy, J-M Ferrero, S Delaloge, Barbara Pistilli, Florence Dalenc, Emmanuelle Jeannot, Luis Augusto Teixeira, Ivan Bièche, Camille Chakiba, J. Grenier, F-C Bidard, J-Y Pierga, Jérôme Lemonnier, Alain Lortholary, Laetitia Stefani, Thomas Bachelot, T. de La Motte Rouge, Sylvain Ladoire, Frédérique Berger, Sibille Everhard, C. Levy, J-P. Jacquin, J-S. Frenel, Renaud Sabatier, Coraline Dubot

Publikováno v: Cancer Research. 79:PD2-06

Background: Palbociclib (Pal) combined with an aromatase inhibitor (AI) is a standard of care as first line therapy in ER+ HER2- metastatic breast cancer (MBC). While ESR1 mutations (ESR1mut) are a characterized mechanism of resistance to AI as singl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::55b1bf1f16cfe1c9557c7370d549125f
https://doi.org/10.1158/1538-7445.sabcs18-pd2-06

Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer

Autor: PH Cottu, J-P. Jacquin, Sylvie Chabaud, M. Campone, J. Grenier, Marc Debled, E. Brain, D. Allouache, Thomas Bachelot, David Cameron, F. Del Piano, Sylvie Giacchetti, Jérôme Lemonnier, Judith M Bliss, M. Brunt, L. Venat Bouvet, Florence Dalenc, Fabrice Andre, J-L Canon, A-C. Hardy Bessard

Publikováno v: Annals of Oncology. 32:574-575

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::497b7ad2ad9117b703ba76aaf012ea89
https://doi.org/10.1016/j.annonc.2021.02.003

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.